Literature DB >> 24033084

Genetic polymorphism of KIR2DL4 (CD158d), a putative NK cell receptor for HLA-G, does not influence susceptibility to asthma.

M E L Le Page1, J P Goodridge, G Zhang, P G Holt, P Sly, C S Witt.   

Abstract

Human leukocyte antigen (HLA)-G is upregulated on the bronchial epithelium of asthma patients and genetic polymorphism affecting expression of HLA-G has been reported to influence susceptibility to asthma. As the NK cell receptor KIR2DL4 has been reported to induce interferon gamma (IFNγ) secretion when ligated with HLA-G, we postulated that the 9A/10A genetic polymorphism of KIR2DL4 which influences receptor structure may influence susceptibility to asthma. KIR2DL4 genotypes were determined in two cohorts of children (n = 219 and n = 1356) in whom total serum IgE, allergen-specific IgE, atopy, bronchial reactivity and asthma symptoms had been studied between birth and 14 years. No reproducible associations with KIR2DL4 genotype were identified, leading us to conclude that the KIR2DL4 9A/10A polymorphism has no influence on susceptibility to asthma.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CD158d; KIR2DL4; asthma; atopy

Mesh:

Substances:

Year:  2013        PMID: 24033084     DOI: 10.1111/tan.12185

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  3 in total

Review 1.  Immunoregulatory Role of HLA-G in Allergic Diseases.

Authors:  Giuseppe Murdaca; Paola Contini; Simone Negrini; Giorgio Ciprandi; Francesco Puppo
Journal:  J Immunol Res       Date:  2016-06-20       Impact factor: 4.818

Review 2.  HLA-G in Allergy: Does It Play an Immunoregulatory Role?

Authors:  Simone Negrini; Paola Contini; Giuseppe Murdaca; Francesco Puppo
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

3.  Possible Role of HLA-G, LILRB1 and KIR2DL4 Gene Polymorphisms in Spontaneous Miscarriage.

Authors:  Izabela Nowak; Andrzej Malinowski; Ewa Barcz; Jacek R Wilczyński; Marta Wagner; Edyta Majorczyk; Hanna Motak-Pochrzęst; Małgorzata Banasik; Piotr Kuśnierczyk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-03-14       Impact factor: 4.291

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.